Creation of ‘olmesartan’ administration prohibition on chronic malabsorption patients

The antihypertensive olmesartan’s safety issue has been settled by newly creating a measure about prohibition of administration on chronic malabsorption syndrome patients in the approval article of olmesartan.

On the 22^nd, the Ministry of Food and Drug Safety(MFDS) announced the notice of change on the approval article as judging necessity of changes on precautions for the use of products cont...